Company profile
Skinvisible, Inc.
OTC: SKVI · Healthcare · Medical - Pharmaceuticals
#1112 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
29DFH 8DQ 59GM 27SS 41
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$20.0k
Rev growth YoY (TTM)
+0.0%
Net income (FY)
-$1.1M
Employees
2
as of 2026-08-26
Market cap
$972.7k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$20.0k$20.0k2025
Net income-$1.1M-$1.1M2025
Operating income-$496.3k-$496.3k2025
Total assets$127.6k$127.6k2025
Liabilities$10.4M$10.4M2025
Equity-$10.3M-$10.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Skinvisible, Inc.’s revenue?
Skinvisible, Inc. booked $20.0k in FY2025 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -5320.2% net margin.
Peers · Healthcare
Doseology Sciences Inc.40DSenti Biosciences, Inc.27DJupiter Neurosciences, Inc.18DSouth American Gold Corp.——THC Farmaceuticals, Inc.——Sector 10, Inc.——Neighbors
Clark →Key facts
CEOTerry H. Howlett
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersLas Vegas, NV
ExchangeOTC: SKVI
Employees2
IPO date1999-01-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.